News Column

Nobel Biocare sues Neodent USA for patent infringement

August 19, 2014

newsbox.ch



Media Release

ZURICH, SWITZERLAND - AUGUST 19, 2014



Nobel Biocare sues Neodent USA for patent infringement



Two subsidiaries of Nobel Biocare Holding AG, a world leader in the field of innovative implant-based dental restorations, filed a patent infringement lawsuit today in California against Neodent USA, Inc., alleging infringement of two patents relating to the innovative design of Nobel Biocare's popular NobelActive® line of dental implants.


In March 2014, Neodent USA launched its line of "Drive CM" dental implants in the US. In its complaint, Nobel Biocare alleges that these implants, imported from Brazil, have striking similarities to the design of the NobelActive® implants which Nobel Biocare commercially launched in 2008. Further, Nobel Biocare asserts that Neodent USA has relied on Nobel Biocare's history of successful clinical data in marketing the Neodent product.


The NobelActive® line has grown to become one of the world's most popular dental implants, supported by Nobel Biocare's commitment to Research & Development (R&D) spending, extensive clinical studies, and training programs for clinicians. Both US patents asserted in the lawsuit relate to technology for aiding the surgical installation and successful integration of the implants in a variety of patient bone types. Nobel Biocare asks the court for an injunction barring sales of Neodent's infringing dental implants, payment of money damages due to Nobel Biocare's lost sales, and to recover its attorney fees for the lawsuit.


Richard Laube, Nobel Biocare's CEO, commented that: "We are committed to enforce our valuable intellectual property rights, which are the result of our industry-leading investment in R&D. We will not tolerate copies of our unique and patented dental implant designs."


Contact information:



SÜha Demokan

Investor & Corporate Relations

Tel: +41 43 211 42 30, +41 79 430 81 46

suha.demokan@nobelbiocare.com






Nobel Biocare (NOBN, SIX Swiss Exchange) is a world leader in the field of innovative implant-based dental restorations. The company's portfolio offers solutions from single tooth to fully edentulous indications with dental implant systems (including key brands NobelActive®, BrÅnemark System® and NobelReplace®), a comprehensive range of high-precision individualized prosthetics and CAD/CAM systems (NobelProcera®), diagnostics, treatment planning and guided surgery solutions (NobelClinician™ and NobelGuide®) and biomaterials (creos™). Nobel Biocare supports its customers through all phases of professional development, offering world-class training and education along with practice support and patient information materials. The company is headquartered in Zurich, Switzerland, currently employs approximately 2,500 employees worldwide and recorded revenue of EUR 566.8 million in 2013. Production takes place at seven sites located in Canada, Israel, Japan, Sweden, and the United States. Products and services are available in over 80 countries through subsidiaries and distributors.



Disclaimer

This media release contains forward-looking statements based on beliefs of Nobel Biocare's management. When used in this media release, words such as "anticipate", "believe", "estimate", "expect", "intend", "plan" and "project" are intended to identify forward-looking statements. They may involve risks and uncertainties, including technological advances in the medical field, product demand and market acceptance, the effect of economic conditions, the impact of competitive products and pricing, foreign currency exchange rates and other risks. These forward-looking statements reflect the views of Nobel Biocare as of the date made with respect to future events and are subject to risks and uncertainties. All of these forward-looking statements are based on estimates and assumptions made by management of the company and are believed to be reasonable, though are inherently uncertain and difficult to predict. Actual results or experience could differ materially from the forward-looking statements. Nobel Biocare disclaims any intention or obligation to update these forward-looking statements.






Media Release (PDF)







Provider

Channel

Contact
Tensid Ltd., Switzerland

www.tensid.ch





newsbox.ch

www.newsbox.ch





Provider/Channel related enquiries

marco@tensid.ch

+41 41 763 00 50


For more stories covering the world of technology, please see HispanicBusiness' Tech Channel



Source: Tensid Regulatory


Story Tools






HispanicBusiness.com Facebook Linkedin Twitter RSS Feed Email Alerts & Newsletters